Immune Mechanisms and Therapeutic Potential of CpG Oligodeoxynucleotides

REFERENCES

• R.S. Chu, O.S. Targoni, A.M. Krieg, P.V. Lehmann, and C.V. Harding, CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity, J. Exp. Med., 186: 1623–1631, 1997. [CSA]
   PubMed Web of Science ®Google Scholar
• G.B. Lipford, M. Bauer, C. Blank, R. Reiter, H. Wagner, and K. Heeg, CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants, Eur. J. Immunol., 27: 2340–2344, 1997. [CSA]
   PubMed Web of Science ®Google Scholar
• H.L. Davis, R. Weeratna, T.J. Waldschmidt, L. Tygrett, J. Schorr, and A.M. Krieg, CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen, J. Immunol., 160: 870–876, 1998. [CSA]
   PubMed Web of Science ®Google Scholar
• M. Roman, E. Martin-Orozco, J.S. Goodman, M.D. Nguyen, Y. Sato, A. Ronaghy, R.S. Kornbluth, D.D. Richman, D.A. Carson, and E. Raz, Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants, Nat. Med., 3: 849–854, 1997. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A.M. Krieg, L. Love-Homan, A.K. Yi, and J.T. Harty, CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge, J. Immunol., 161: 2428–2434, 1998. [CSA]
   PubMed Web of Science ®Google Scholar
• D.G. Rees, A.J. Gates, M. Green, L. Eastaugh, R.A. Lukaszewski, K.F. Griffin, A.M. Krieg, and R.W. Titball, CpG-DNA protects against a lethal orthopoxvirus infection in a murine model, Antiviral Res., 65: 87–95, 2005. [CSA], [CROSSREF]
   Google Scholar
• J.C. Deng, T.A. Moore, M.W. Newstead, X. Zeng, A.M. Krieg, and T.J. Standiford, CpG oligodeoxynucleotides stimulate protective innate immunity against pulmonary Klebsiella infection, J. Immunol., 173: 5148–5155, 2004. [CSA]
   PubMed Web of Science ®Google Scholar
• R.A. Gramzinski, D.L. Doolan, M. Sedegah, H.L. Davis, A.M. Krieg, and S.L. Hoffman, Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice, Infect. Immun., 69: 1643–1649, 2001. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• X.P. Ioannou, P. Griebel, R. Hecker, L.A. Babiuk, and S. van Drunen Littel-van den Hurk, The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxynucleotides, J. Virol., 76: 9002–9010, 2002. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• R.D. Weeratna, C.L. Brazolot Millan, M.J. McCluskie, and H.L. Davis, CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice, FEMS Immunol. Med. Microbiol., 32: 65–71, 2001. [CSA], [CROSSREF]
   PubMedGoogle Scholar
• M. Lazarczyk, K. Grzela, and T. Grzela, Immunostimulatory oligonucleotides in therapy of allergic diseases, Expert. Opin. Biol. Ther., 5: 525–536, 2005. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Y. Meng, A.F. Carpentier, L. Chen, G. Boisserie, J.M. Simon, J.J. Mazeron, and J.Y. Delattre, Successful combination of local CpG-ODN and radiotherapy in malignant glioma, Int. J. Cancer, 116: 992–997, 2005. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A.M. Krieg, From bugs to drugs: Therapeutic immunomodulation with oligodeoxynucleotides containing CpG sequences from bacterial DNA, Antisense Nucleic. Acid. Drug. Dev., 11: 181–188, 2001. [CSA], [CROSSREF]
   PubMedGoogle Scholar
• C. Hashimoto, K.L. Hudson, and K.V. Anderson, The Toll gene of Drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein, Cell, 52: 269–279, 1988. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• B. Lemaitre, E. Nicolas, L. Michaut, J.M. Reichhart, and J.A. Hoffmann, The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults, Cell, 86: 973–983, 1996. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• N.J. Gay and F.J. Keith, Drosophila Toll and IL-1 receptor, Nature, 351: 355–356, 1991. [CSA]
   PubMed Web of Science ®Google Scholar
• F.L. Rock, G. Hardiman, J.C. Timans, R.A. Kastelein, and J.F. Bazan, A family of human receptors structurally related to Drosophila Toll, Proc. Natl. Acad. Sci. U. S. A., 95: 588–593, 1998. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• P. Kirk and J.F. Bazan, Pathogen recognition: TLRs throw us a curve, Immunity, 23: 347–350, 2005. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• G.M. Barton and R. Medzhitov, Toll-like receptor signaling pathways, Science, 300: 1524–1525, 2003. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• J.J. Gao, V. Diesl, T. Wittmann, D.C. Morrison, J.L. Ryan, S.N. Vogel, and M.T. 'Follettie, Bacterial LPS and CpG DNA differentially induce gene expression profiles in mouse macrophages, J. Endotoxin Res., 9: 237–243, 2003. [CSA], [CROSSREF]
   Google Scholar
• P.J. Griebel, R. Brownlie, A. Manuja, A. Nichani, N. Mookherjee, Y. Popowych, G. 'Mutwiri, R. Hecker, and L.A. Babiuk, Bovine toll-like receptor 9: a comparative analysis of molecular structure, function and expression, Vet Immunol. Immunopathol., 108: 11–16, 2005. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• H. Hemmi, O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M. Matsumoto, K. 'Hoshino, H. Wagner, K. Takeda, and S. Akira, A Toll-like receptor recognizes bacterial DNA, Nature, 408: 740–745, 2000. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A.P. Bird, CpG-rich islands and the function of DNA methylation, Nature, 321: 209–213, 1986. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A.M. Krieg, CpG motifs in bacterial DNA and their immune effects, Annu. Rev. Immunol., 20: 709–760, 2002. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A.M. Krieg, A.K. Yi, S. Matson, T.J. Waldschmidt, G.A. Bishop, R. Teasdale, G.A. 'Koretzky, and D.M. Klinman, CpG motifs in bacterial DNA trigger direct B-cell activation, Nature, 374: 546–549, 1995. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• S. Bauer, C.J. Kirschning, H. Hacker, V. Redecke, S. Hausmann, S. Akira, H. 'Wagner, and G.B. Lipford, Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition, Proc. Natl. Acad. Sci. U. S. A., 98: 9237–9242, 2001. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• F. Takeshita, C.A. Leifer, I. Gursel, K.J. Ishii, S. Takeshita, M. Gursel, and D.M. Klinman, Cutting edge: role of Toll-like receptor 9 in CpG DNA-induced activation of human cells, J. Immunol., 167: 3555–3558, 2001. [CSA]
   PubMed Web of Science ®Google Scholar
• E.R. Kandimalla, L. Bhagat, F.G. Zhu, D. Yu, Y.P. Cong, D. Wang, J.X. Tang, J.Y. 'Tang, C.F. Knetter, E. Lien, and S. Agrawal, A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif, Proc. Natl. Acad. Sci. U. S. A., 100: 14303–14308, 2003. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A. Krug, S. Rothenfusser, V. Hornung, B. Jahrsdorfer, S. Blackwell, Z.K. Ballas, S. 'Endres, A.M. Krieg, and G. Hartmann, Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells, Eur. J. Immunol., 31: 2154–2163, 2001. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• J.D. Marshall, K. Fearon, C. Abbate, S. Subramanian, P. Yee, J. Gregorio, R.L. Coffman, and G. Van Nest, Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions, J. Leukoc. Biol., 73: 781–792, 2003. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• G.B. Lipford, S. Bendigs, K. Heeg, and H. Wagner, Poly-guanosine motifs costimulate antigen-reactive CD8 T cells while bacterial CpG-DNA affect T-cell activation via antigen-presenting cell-derived cytokines, Immunology, 101: 46–52, 2000. [CSA], [CROSSREF]
   Google Scholar
• G. Hartmann and A.M. Krieg, Mechanism and function of a newly identified CpG DNA motif in human primary B cells, J. Immunol., 164: 944–953, 2000. [CSA]
   PubMed Web of Science ®Google Scholar
• C.C. Wu, J. Lee, E. Raz, M. Corr, and D.A. Carson, Necessity of oligonucleotide aggregation for toll-like receptor 9 activation, J. Biol. Chem., 279: 33071–33078, 2004. [CSA], [CROSSREF]
   Google Scholar
• M. Rutz, J. Metzger, T. Gellert, P. Luppa, G.B. Lipford, H. Wagner, and S. Bauer, Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner, Eur. J. Immunol., 34: 2541–2550, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Q. Zhao, S. Matson, C.J. Herrera, E. Fisher, H. Yu, and A.M. Krieg, Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides, Antisense Res. Dev., 3: 53–66, 1993. [CSA]
   PubMedGoogle Scholar
• D.P. Sester, S. Naik, S.J. Beasley, D.A. Hume and K.J. Stacey, Phosphorothioate backbone modification modulates macrophage activation by CpG DNA, J. Immunol., 165: 4165–4173, 2000. [CSA]
   PubMed Web of Science ®Google Scholar
• K.H. Baek, S.J. Ha, and Y.C. Sung, A novel function of phosphorothioate oligodeoxynucleotides as chemoattractants for primary macrophages, J. Immunol., 167: 2847–2854, 2001. [CSA]
   Google Scholar
• Z. Khaled, L. Benimetskaya, R. Zeltser, T. Khan, H.W. Sharma, R. Narayanan, and C.A. Stein, Multiple mechanisms may contribute to the cellular anti-adhesive effects of phosphorothioate oligodeoxynucleotides, Nucleic Acids Res., 24: 737–745, 1996. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• D.K. Monteith, S.P. Henry, R.B. Howard, S. Flournoy, A.A. Levin, C.F. Bennett, and S.T. Crooke, Immune stimulation–a class effect of phosphorothioate oligodeoxynucleotides in rodents, Anticancer Drug Des., 12: 421–432, 1997. [CSA]
   PubMedGoogle Scholar
• R. Rankin, R. Pontarollo, X. Ioannou, A.M. Krieg, R. Hecker, L.A. Babiuk, and S. van Drunen Littel-van den Hurk, CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved, Antisense Nucleic Acid Drug Dev., 11: 333–340, 2001. [CSA], [CROSSREF]
   PubMedGoogle Scholar
• D. Verthelyi, R.T. Kenney, R.A. Seder, A.A. Gam, B. Friedag, and D.M. Klinman, CpG oligodeoxynucleotides as vaccine adjuvants in primates, J. Immunol., 168: 1659–1663, 2002. [CSA]
   PubMed Web of Science ®Google Scholar
• D. Verthelyi and D.M. Klinman, Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates, Clin. Immunol., 109: 64–71, 2003. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• H.L. Davis, I.I. Suparto, R.R. Weeratna, Jumintarto, D.D. Iskandriati, S.S. Chamzah, A.A. Ma'ruf, C.C. Nente, D.D. Pawitri, A.M. Krieg, Heriyanto, W. Smits, and D.D. Sajuthi, CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans, Vaccine, 18: 1920–1924, 2000. [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• H. Hacker, H. Mischak, T. Miethke, S. Liptay, R. Schmid, T. Sparwasser, K. Heeg, G.B. Lipford, and H. Wagner, CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation, Embo. J., 17: 6230–6240, 1998. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• E. Latz, A. Schoenemeyer, A. Visintin, K.A. Fitzgerald, B.G. Monks, C.F. Knetter, E. Lien, N.J. Nilsen, T. Espevik, and D.T. Golenbock, TLR9 signals after translocating from the ER to CpG DNA in the lysosome, Nat. Immunol., 5: 190–198, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• E. Latz, A. Visintin, T. Espevik, and D.T. Golenbock, Mechanisms of TLR9 activation, J. Endotoxin. Res., 10: 406–412, 2004. [CSA], [CROSSREF]
   Google Scholar
• K.J. Ishii, F. Takeshita, I. Gursel, M. Gursel, J. Conover, A. Nussenzweig, and D.M. Klinman, Potential role of phosphatidylinositol 3 kinase, rather than DNA-dependent protein kinase, in CpG DNA-induced immune activation, J. Exp. Med., 196: 269–274, 2002. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• K. Honda, Y. Ohba, H. Yanai, H. Negishi, T. Mizutani, A. Takaoka, C. Taya, and T. Taniguchi, Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction, Nature, 434: 1035–1040, 2005. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• M. Gursel, D. Verthelyi, I. Gursel, K.J. Ishii, and D.M. Klinman, Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. J. Leukoc. Biol., 71: 813–820, 2002. [CSA]
   PubMed Web of Science ®Google Scholar
• T. Jakob, P.S. Walker, A.M. Krieg, M.C. Udey, and J.C. Vogel, Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA, J. Immunol., 161: 3042–3049, 1998. [CSA]
   PubMed Web of Science ®Google Scholar
• G. Hartmann and A.M. Krieg, CpG DNA and LPS induce distinct patterns of activation in human monocytes, Gene. Ther., 6: 893–903, 1999. [CSA]
   PubMed Web of Science ®Google Scholar
• T. Sparwasser, T. Miethke, G. Lipford, A. Erdmann, H. Hacker, K. Heeg, and H. Wagner, Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. Eur. J. Immunol., 27: 1671–1679, 1997. [CSA]
   PubMed Web of Science ®Google Scholar
• K.J. Stacey, M.J. Sweet, and D.A. Hume, Macrophages ingest and are activated by bacterial DNA, J. Immunol., 157: 2116–2122, 1996. [CSA]
   PubMed Web of Science ®Google Scholar
• D.M. Klinman, F. Takeshita, I. Gursel, C. Leifer, K.J. Ishii, D. Verthelyi, and M. Gursel, CpG DNA: recognition by and activation of monocytes, Microbes Infect., 4: 897–901, 2002. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A.K. Yi, J.H. Chace, J.S. Cowdery, and A.M. Krieg, IFN-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides, J. Immunol., 156: 558–564, 1996. [CSA]
   PubMed Web of Science ®Google Scholar
• A.K. Yi, P. Hornbeck, D.E. Lafrenz, and A.M. Krieg, CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL, J. Immunol., 157: 4918–4925, 1996. [CSA]
   PubMed Web of Science ®Google Scholar
• T.W. Redford, A.K. Yi, C.T. Ward, and A.M. Krieg, Cyclosporin A enhances IL-12 production by CpG motifs in bacterial DNA and synthetic oligodeoxynucleotides, J. Immunol., 161: 3930–3935, 1998. [CSA]
   Google Scholar
• B. Jahrsdorfer, G. Hartmann, E. Racila, W. Jackson, L. Muhlenhoff, G. Meinhardt, S. Endres, B.K. Link, A.M. Krieg, and G.J. Weiner, CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens, J. Leukoc. Biol., 69: 81–88, 2001. [CSA]
   PubMed Web of Science ®Google Scholar
• S. Sun, C. Beard, R. Jaenisch, P. Jones, and J. Sprent, Mitogenicity of DNA from different organisms for murine B cells, J. Immunol., 159: 3119–3125, 1997. [CSA]
   PubMed Web of Science ®Google Scholar
• D. Verthelyi, K.J. Ishii, M. Gursel, F. Takeshita, and D.M. Klinman, Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs, J. Immunol., 166: 2372–2377, 2001. [CSA]
   PubMed Web of Science ®Google Scholar
• L. Tasker and S. Marshall-Clarke, Functional responses of human neonatal B lymphocytes to antigen receptor cross-linking and CpG DNA, Clin. Exp. Immunol., 134: 409–419, 2003. [CSA], [CROSSREF]
   Google Scholar
• A.M. Krieg, A.K. Yi, and G. Hartmann, Mechanisms and therapeutic applications of immune stimulatory CpG DNA, Pharmacol. Ther., 84: 113–120, 1999. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• S.J. Szabo, S.T. Kim, G.L. Costa, X. Zhang, C.G. Fathman, and L.H. Glimcher, A novel transcription factor, T-bet, directs Th1 lineage commitment, Cell, 100: 655–669, 2000. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• N. Liu, N. Ohnishi, L. Ni, S. Akira, and K.B. Bacon, CpG directly induces T-bet expression and inhibits IgG1 and IgE switching in B cells, Nat. Immunol., 4: 687–693, 2003. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• N. Kadowaki, S. Ho, S. Antonenko, R.W. Malefyt, R.A. Kastelein, F. Bazan, and Y.J. Liu, Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens, J. Exp. Med., 194: 863–869, 2001. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Z. Guo, S. Garg, K.M. Hill, L. Jayashankar, M.R. Mooney, M. Hoelscher, J.M. Katz, J.M. Boss, and S. Sambhara, A distal regulatory region is required for constitutive and IFN-beta-induced expression of murine TLR9 gene, J. Immunol., 175: 7407–7418, 2005. [CSA]
   Google Scholar
• G. Hartmann, G.J. Weiner, and A.M. Krieg, CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells, Proc. Natl. Acad. Sci. U. S. A., 96: 9305–9310, 1999. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• T. Sparwasser, E.S. Koch, R.M. Vabulas, K. Heeg, G.B. Lipford, J.W. Ellwart, and H. Wagner, Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells, Eur. J. Immunol., 28: 2045–2054, 1998. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• J.S. Cowdery, J.H. Chace, A.K. Yi, and A.M. Krieg, Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides, J. Immunol., 156: 4570–4575, 1996. [CSA]
   PubMed Web of Science ®Google Scholar
• Y. Sato, M. Roman, H. Tighe, D. Lee, M. Corr, M.D. Nguyen, G.J. Silverman, M. Lotz, D.A. Carson, and E. Raz, Immunostimulatory DNA sequences necessary for effective intradermal gene immunization, Science, 273: 352–354, 1996. [CSA]
   PubMed Web of Science ®Google Scholar
• K.J. Stacey, D.P. Sester, M.J. Sweet, and D.A. Hume, Macrophage activation by immunostimulatory DNA, Curr. Top Microbiol. Immunol., 247: 41–58, 2000. [CSA]
   PubMed Web of Science ®Google Scholar
• J.D. Powell, S. Boodoo, and M.R. Horton, Identification of the molecular mechanism by which TLR ligation and IFN-gamma synergize to induce MIG. Clin. Dev. Immunol., 11: 77–85, 2004. [CSA], [CROSSREF]
   Google Scholar
• R.S. Chu, D. Askew, E.H. Noss, A. Tobian, A.M. Krieg, and C.V. Harding, CpG oligodeoxynucleotides down-regulate macrophage class II MHC antigen processing, J. Immunol., 163: 1188–1194, 1999. [CSA]
   Google Scholar
• R. Takauji, S. Iho, H. Takatsuka, S. Yamamoto, T. Takahashi, H. Kitagawa, H. Iwasaki, R. Iida, T. Yokochi, and T. Matsuki, CpG-DNA-induced IFN-{alpha} production involves p38 MAPK-dependent STAT1 phosphorylation in human plasmacytoid dendritic cell precursors, J. Leukoc. Biol., 72: 1011–1019, 2002. [CSA]
   PubMed Web of Science ®Google Scholar
• G.B. Lipford, K. Heeg, and H. Wagner, Bacterial DNA as immune cell activator, Trends Microbiol., 6: 496–500, 1998. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A.M. Krieg, The role of CpG motifs in innate immunity. Curr. Opin. Immunol., 12: 35–43, 2000. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• D.M. Klinman, Use of CpG oligodeoxynucleotides as immunoprotective agents, Expert Opin. Biol. Ther., 4: 937–946, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• E.J. Pearce, C.M. Kane, and J. Sun, Regulation of dendritic cell function by pathogen-derived molecules plays a key role in dictating the outcome of the adaptive immune response, Chem. Immunol. Allergy, 90: 82–90, 2006. [CSA]
   PubMedGoogle Scholar
• S. Sun, X. Zhang, D.F. Tough, and J. Sprent, Type I interferon-mediated stimulation of T cells by CpG DNA, J. Exp. Med., 188: 2335–2342, 1998. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• K. Kranzer, M. Bauer, G.B. Lipford, K. Heeg, H. Wagner, and R. Lang, CpG-oligodeoxynucleotides enhance T-cell receptor-triggered interferon-gamma production and up-regulation of CD69 via induction of antigen-presenting cell-derived interferon type I and interleukin-12, Immunology, 99: 170–178, 2000. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• R.A. Pontarollo, R. Rankin, L.A. Babiuk, D.L. Godson, P.J. Griebel, R. Hecker, A.M. Krieg, and S. van Drunen Littel-van den Hurk, Monocytes are required for optimum in vitro stimulation of bovine peripheral blood mononuclear cells by non-methylated CpG motifs, Vet Immunol. Immunopathol., 84: 43–59, 2002. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• S. Rothenfusser, V. Hornung, M. Ayyoub, S. Britsch, A. Towarowski, A. Krug, A. Sarris, N. Lubenow, D. Speiser, S. Endres, and G. Hartmann, CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro, Blood, 103: 2162–2169, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• S. Sivori, M. Falco, M. Della Chiesa, S. Carlomagno, M. Vitale, L. Moretta, and A. Moretta, CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells, Proc. Natl. Acad. Sci. U. S. A., 101: 10116–10121, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Z.K. Ballas, A.M. Krieg, T. Warren, W. Rasmussen, H.L. Davis, M. Waldschmidt, and G.J. Weiner, Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs, J. Immunol., 167: 4878–4886, 2001. [CSA]
   PubMed Web of Science ®Google Scholar
• Z.K. Ballas, W.L. Rasmussen, and A.M. Krieg, Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA, J. Immunol., 157: 1840–1845, 1996. [CSA]
   PubMed Web of Science ®Google Scholar
• C.A. Biron, K.B. Nguyen, G.C. Pien, L.P. Cousens, and T.P. Salazar-Mather, Natural killer cells in antiviral defense: function and regulation by innate cytokines, Annu. Rev. Immunol., 17: 189–220, 1999. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• B.O. Noll, M.J. McCluskie, T. Sniatala, A. Lohner, S. Yuill, A.M. Krieg, C. Schetter, H.L. Davis, and E. Uhlmann, Biodistribution and metabolism of immunostimulatory oligodeoxynucleotide CPG 7909 in mouse and rat tissues following subcutaneous administration, Biochem. Pharmacol., 69: 981–991, 2005. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A.K. Nichani, A. Mena, Y. Popowych, D. Dent, H.G. Townsend, G.K. Mutwiri, R. Hecker, L.A. Babiuk, and P.J. Griebel, In vivo immunostimulatory effects of CpG oligodeoxynucleotide in cattle and sheep, Vet Immunol. Immunopathol., 98: 17–29, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A.A. Ashkar, S. Bauer, W.J. Mitchell, J. Vieira, and K.L. Rosenthal, Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2. J. Virol., 77: 8948–8956, 2003. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• K.L. Elkins, T.R. Rhinehart-Jones, S. Stibitz, J.S. Conover, and D.M. Klinman, Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria, J. Immunol., 162: 2291–2298, 1999. [CSA]
   PubMed Web of Science ®Google Scholar
• P.S. Walker, T. Scharton-Kersten, A.M. Krieg, L. Love-Homan, E.D. Rowton, M.C. Udey, and J.C. Vogel, Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms, Proc. Natl. Acad. Sci. U. S. A., 96: 6970–6975, 1999. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• N.P. Juffermans, J.C. Leemans, S. Florquin, A. Verbon, A.H. Kolk, P. Speelman, S.J. van Deventer, and T. van der Poll, CpG oligodeoxynucleotides enhance host defense during murine tuberculosis, Infect. Immun., 70: 147–152, 2002. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• S. Zimmermann, O. Egeter, S. Hausmann, G.B. Lipford, M. Rocken, H. Wagner, and K. Heeg, CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis, J. Immunol., 160: 3627–3630, 1998. [CSA]
   PubMed Web of Science ®Google Scholar
• D.M. Klinman, J. Conover, and C. Coban, Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection, Infect. Immun., 67: 5658–5663, 1999. [CSA]
   PubMed Web of Science ®Google Scholar
• D. Verthelyi, M. Gursel, R.T. Kenney, J.D. Lifson, S. Liu, J. Mican, and D.M. Klinman, CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection, J. Immunol., 170: 4717–4723, 2003. [CSA]
   PubMed Web of Science ®Google Scholar
• B. Flynn, V. Wang, D.L. Sacks, R.A. Seder, and D. Verthelyi, Prevention and treatment of cutaneous leishmaniasis in primates by using synthetic type D/A oligodeoxynucleotides expressing CpG motifs, Infect. Immun., 73: 4948–4954, 2005. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• S. Gomis, L. Babiuk, D.L. Godson, B. Allan, T. Thrush, H. Townsend, P. Willson, E. Waters, R. Hecker, and A. Potter, Protection of chickens against Escherichia coli infections by DNA containing CpG motifs, Infect. Immun., 71: 857–863, 2003. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• H. He, V.K. Lowry, C.L. Swaggerty, P.J. Ferro, and M.H. Kogut, In vitro activation of chicken leukocytes and in vivo protection against Salmonella enteritidis organ invasion and peritoneal S. enteritidis infection-induced mortality in neonatal chickens by immunostimulatory CpG oligodeoxynucleotide, FEMS Immunol. Med. Microbiol., 43: 81–89, 2005. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A.K. Nichani, A. Mena, R.S. Kaushik, G.K. Mutwiri, H.G.G. Townsend, R. Hecker, A.M. Krieg, L.A. Babiuk, and P.J. Griebel, Stimulation of Innate Immune Responses by CpG Oligodeoxynucleotide in Newborn Lambs can Reduce Bovine Herpes Virus-1 Shedding, Oligonucleotides, 16: 57–66, 2006. [CSA]
   Google Scholar
• L. Rice, D. Orlow, K. Ceonzo, G.L. Stahl, A.O. Tzianabos, H. Wada, W.C. Aird, and J.A. Buras, CpG oligodeoxynucleotide protection in polymicrobial sepsis is dependent on interleukin-17, J. Infect. Dis., 191: 1368–1376, 2005. [CSA], [CROSSREF]
   Google Scholar
• S. Ito, K.J. Ishii, A. Ihata, and D.M. Klinman, Contribution of nitric oxide to CpG-mediated protection against Listeria monocytogenes, Infect. Immun., 73: 3803–3805, 2005. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• M.T. Harte, I.R. Haga, G. Maloney, P. Gray, P.C. Reading, N.W. Bartlett, G.L. Smith, A. Bowie, and L.A. O'Neill, The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense, J. Exp. Med., 197: 343–351, 2003. [CSA]
   PubMed Web of Science ®Google Scholar
• S. Ito, J. Pedras-Vasconcelos, and D.M. Klinman, CpG oligodeoxynucleotides increase the susceptibility of normal mice to infection by Candida albicans, Infect. Immun., 73: 6154–6156, 2005. [CSA]
   Google Scholar
• C.L. Cooper, H.L. Davis, M.L. Morris, S.M. Efler, M.A. Adhami, A.M. Krieg, D.W. Cameron, and J. Heathcote, CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J. Clin. Immunol., 24: 693–701, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• C.L. Cooper, H.L. Davis, J.B. Angel, M.L. Morris, S.M. Elfer, I. Seguin, A.M. Krieg, and D.W. Cameron, CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults, Aids, 19: 1473–1479, 2005. [CSA]
   PubMed Web of Science ®Google Scholar
• M. Singh, J.R. Carlson, M. Briones, M. Ugozzoli, J. Kazzaz, J. Barackman, G. Ott, and D. O'Hagan, A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2, Vaccine, 16: 1822–1827, 1998. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• J.P. Valensi, J.R. Carlson, and G.A. Van Nest, Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants, J. Immunol., 153: 4029–4039, 1994. [CSA]
   PubMed Web of Science ®Google Scholar
• X.P. Ioannou, S.M. Gomis, B. Karvonen, R. Hecker, L.A. Babiuk, and S. van Drunen Littel-van den Hurk, CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein, Vaccine, 21: 127–137, 2002. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• R. Rankin, R. Pontarollo, S. Gomis, B. Karvonen, P. Willson, B.I. Loehr, D.L. Godson, L.A. Babiuk, R. Hecker, and S. van Drunen Littel-van den Hurk, CpG-containing oligodeoxynucleotides augment and switch the immune responses of cattle to bovine herpesvirus-1 glycoprotein D, Vaccine, 20: 3014–3022, 2002. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• S.K. Datta, H.J. Cho, K. Takabayashi, A.A. Horner, and E. Raz, Antigen-immunostimulatory oligonucleotide conjugates: mechanisms and applications. Immunol. Rev., 199: 217–226, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• H. Tighe, K. Takabayashi, D. Schwartz, G. Van Nest, S. Tuck, J.J. Eiden, A. Kagey-Sobotka, P.S. Creticos, L.M. Lichtenstein, H.L. Spiegelberg, and E. Raz, Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity, J. Allergy Clin. Immunol., 106: 124–134, 2000. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• D.H. Broide, G. Stachnick, D. Castaneda, J. Nayar, M. Miller, J.Y. Cho, M. Roman, J. Zubeldia, T. Hayashi, and E. Raz, Systemic administration of immunostimulatory DNA sequences mediates reversible inhibition of Th2 responses in a mouse model of asthma. J. Clin. Immunol., 21: 175–182, 2001. [CSA], [CROSSREF]
   PubMedGoogle Scholar
• J.N. Kline, T.J. Waldschmidt, T.R. Businga, J.E. Lemish, J.V. Weinstock, P.S. Thorne, and A.M. Krieg, Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma, J. Immunol., 160: 2555–2559, 1998. [CSA]
   PubMed Web of Science ®Google Scholar
• R.K. Ikeda, J. Nayar, J.Y. Cho, M. Miller, M. Rodriguez, E. Raz, and D.H. Broide, Resolution of airway inflammation following ovalbumin inhalation: comparison of ISS DNA and corticosteroids, Am. J. Respir. Cell. Mol. Biol., 28: 655–663, 2003. [CSA], [CROSSREF]
   Google Scholar
• D. Serebrisky, A.A. Teper, C.K. Huang, S.Y. Lee, T.F. Zhang, B.H. Schofield, M. Kattan, H.A. Sampson, and X.M. Li, CpG oligodeoxynucleotides can reverse Th2-associated allergic airway responses and alter the B7.1/B7.2 expression in a murine model of asthma, J. Immunol., 165: 5906–5912, 2000. [CSA]
   Google Scholar
• J.Y. Cho, M. Miller, K.J. Baek, J.W. Han, J. Nayar, M. Rodriguez, S.Y. Lee, K. McElwain, S. McElwain, E. Raz, and D.H. Broide, Immunostimulatory DNA inhibits transforming growth factor-beta expression and airway remodeling. Am. J. Respir. Cell. Mol. Biol., 30: 651–661, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• C.J. Youn, M. Miller, K.J. Baek, J.W. Han, J. Nayar, S.Y. Lee, K. McElwain, S. McElwain, E. Raz, and D.H. Broide, Immunostimulatory DNA reverses established allergen-induced airway remodeling, J. Immunol., 173: 7556–7564, 2004. [CSA]
   PubMed Web of Science ®Google Scholar
• M.V. Fanucchi, E.S. Schelegle, G.L. Baker, M.J. Evans, R.J. McDonald, L.J. Gershwin, E. Raz, D.M. Hyde, C.G. Plopper, and L.A. Miller, Immunostimulatory oligonucleotides attenuate airways remodeling in allergic monkeys, Am. J. Respir. Crit. Care Med., 170: 1153–1157, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• F.E. Simons, Y. Shikishima, G. Van Nest, J.J. Eiden, and K.T. HayGlass, Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA, J. Allergy Clin. Immunol., 113: 1144–1151, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• M.K. Tulic, P.O. Fiset, P. Christodoulopoulos, P. Vaillancourt, M. Desrosiers, F. Lavigne, J. Eiden, and Q. Hamid, Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J. Allergy Clin. Immunol., 113: 235–241, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A.A. Horner, J.H. Van Uden, J.M. Zubeldia, D. Broide, and E. Raz, DNA-based immunotherapeutics for the treatment of allergic disease, Immunol. Rev., 179: 102–118, 2001. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A.A. Horner, G.F. Widhopf, J.A. Burger, K. Takabayashi, N. Cinman, A. Ronaghy, H.L. Spiegelberg, and E. Raz, Immunostimulatory DNA inhibits IL-4-dependent IgE synthesis by human B cells, J. Allergy Clin. Immunol., 108: 417–423, 2001. [CSA], [CROSSREF]
   Google Scholar
• M.G. Chiaramonte, M. Hesse, A.W. Cheever, and T.A. Wynn, CpG oligonucleotides can prophylactically immunize against Th2-mediated schistosome egg-induced pathology by an IL-12-independent mechanism, J. Immunol., 164: 973–985, 2000. [CSA]
   PubMed Web of Science ®Google Scholar
• J.N. Kline, A.M. Krieg, T.J. Waldschmidt, Z.K. Ballas, V. Jain, and T.R. Businga, CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma, J. Allergy Clin. Immunol., 104: 1258–1264, 1999. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• E.M. Hessel, M. Chu, J.O. Lizcano, B. Chang, N. Herman, S.A. Kell, M. Wills-Karp, and R.L. Coffman, Immunostimulatory oligonucleotides block allergic airway inflammation by inhibiting Th2 cell activation and IgE-mediated cytokine induction, J. Exp. Med., 202: 1563–1573, 2005. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• T. Hayashi, L. Beck, C. Rossetto, X. Gong, O. Takikawa, K. Takabayashi, D.H. Broide, D.A. Carson, and E. Raz, Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J. Clin. Invest., 114: 270–279, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• J.E. Wooldridge, Z. Ballas, A.M. Krieg, and G.J. Weiner, Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma, Blood, 89: 2994–2998, 1997. [CSA]
   PubMed Web of Science ®Google Scholar
• J.B. Smith and E. Wickstrom, Antisense c-myc and immunostimulatory oligonucleotide inhibition of tumorigenesis in a murine B-cell lymphoma transplant model, J. Natl. Cancer Inst., 90: 1146–1154, 1998. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A.F. Carpentier, J. Xie, K. Mokhtari, and J.Y. Delattre, Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs, Clin. Cancer Res., 6: 2469–2473, 2000. [CSA]
   PubMed Web of Science ®Google Scholar
• G. Auf, A.F. Carpentier, L. Chen, C. Le Clanche, and J.Y. Delattre, Implication of macrophages in tumor rejection induced by CpG-oligodeoxynucleotides without antigen, Clin. Cancer Res., 7: 3540–3543, 2001. [CSA]
   PubMed Web of Science ®Google Scholar
• Y. Meng, A.F. Carpentier, L. Chen, G. Boisserie, J.M. Simon, J.J. Mazeron, and J.Y. Delattre, Successful combination of local CpG-ODN and radiotherapy in malignant glioma, Int. J. Cancer, 116: 992–997, 2005. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• D.E. Speiser, D. Lienard, N. Rufer, V. Rubio-Godoy, D. Rimoldi, F. Lejeune, A.M. Krieg, J.C. Cerottini, and P. Romero, Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909, J. Clin. Invest., 115: 739–746, 2005. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A.F. Carpentier, [Cancer immunotherapy with CpG-ODN] Med. Sci. (Paris), 21: 73–77, 2005. [CSA]
   Google Scholar
• W.M. Chamberlin and S.A. Naser, Integrating theories of the etiology of Crohn's disease. On the etiology of Crohn's disease: questioning the hypotheses, Med. Sci. Monit., 12: RA27–RA33, 2006. [CSA]
   PubMed Web of Science ®Google Scholar
• D. Rachmilewitz, F. Karmeli, K. Takabayashi, T. Hayashi, L. Leider-Trejo, J. Lee, L.M. Leoni, and E. Raz, Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis, Gastroenterology, 122: 1428–1441, 2002. [CSA], [CROSSREF]
   PubMedGoogle Scholar
• F. Obermeier, N. Dunger, L. Deml, H. Herfarth, J. Scholmerich, and W. Falk, CpG motifs of bacterial DNA exacerbate colitis of dextran sulfate sodium-treated mice, Eur. J. Immunol., 32: 2084–2092, 2002. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• F. Obermeier, N. Dunger, U.G. Strauch, N. Grunwald, H. Herfarth, J. Scholmerich, and W. Falk, Contrasting activity of cytosin-guanosin dinucleotide oligonucleotides in mice with experimental colitis, Clin. Exp. Immunol., 134: 217–224, 2003. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• C.A. Siegrist, Neonatal and early life vaccinology, Vaccine, 19: 3331–3346, 2001. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• S. Ito, K.J. Ishii, M. Gursel, H. Shirotra, A. Ihata, and D.M. Klinman, CpG oligodeoxynucleotides enhance neonatal resistance to Listeria infection, J. Immunol., 174: 777–782, 2005. [CSA]
   PubMed Web of Science ®Google Scholar
• S. Ito, K.J. Ishii, H. Shirota, and D.M. Klinman, CpG oligodeoxynucleotides improve the survival of pregnant and fetal mice following Listeria monocytogenes infection, Infect. Immun., 72: 3543–3548, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• C. Barrios, P. Brawand, M. Berney, C. Brandt, P.H. Lambert, and C.A. Siegrist, Neonatal and early life immune responses to various forms of vaccine antigens qualitatively differ from adult responses: predominance of a Th2-biased pattern which persists after adult boosting, Eur. J. Immunol., 26: 1489–1496, 1996. [CSA]
   Google Scholar
• A.K. Nichani, A. Mena, S.K. Radhey, G.K. Mutwiri, H.G. Townsend, R. Hecker, A.M. Krieg, L.A. Babiuk, and P. Griebel, Stimulation of innate immune responses by CpG oligodeoxynucleotide in newborn lambs can reduce bovine herpes virus-1 shedding, OLIGONUCLEOTIDES, 16: 58–67, 2006. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Z. Linghua, G. Yong, T. Xingshan, and Z. Fengzhen, Co-administration of porcine-specific CpG oligodeoxynucleotide enhances the immune responses to pseudorabies attenuated virus vaccine in newborn piglets in vivo, Dev. Comp. Immunol., 30: 589–596, 2006. [CSA], [CROSSREF]
   Google Scholar
• C.D. Landers and S. Bondada, CpG oligodeoxynucleotides stimulate cord blood mononuclear cells to produce immunoglobulins, Clin. Immunol., 116: 236–245, 2005. [CSA], [CROSSREF]
   Google Scholar
• N.L. Bernasconi, N. Onai, and A. Lanzavecchia, A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells, Blood, 101: 4500–4504, 2003. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• D. De Wit, V. Olislagers, S. Goriely, F. Vermeulen, H. Wagner, M. Goldman, and F. Willems, Blood plasmacytoid dendritic cell responses to CpG oligodeoxynucleotides are impaired in human newborns, Blood, 103: 1030–1032, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A.M. Krieg, S.M. Efler, M. Wittpoth, M.J. Al Adhami, and H.L. Davis, Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist, J. Immunother., 27: 460–471, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• G. Wingender, N. Garbi, B. Schumak, F. Jungerkes, E. Endl, D. von Bubnoff, J. Steitz, J. Striegler, G. Moldenhauer, T. Tuting, A. Heit, K.M. Huster, O. Takikawa, S. Akira, D.H. Busch, H. Wagner, G.J. Hammerling, P.A. Knolle, and A. Limmer, Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO, Eur. J. Immunol., 36: 12–20, 2006. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• M. Heikenwalder, M. Polymenidou, T. Junt, C. Sigurdson, H. Wagner, S. Akira, R. Zinkernagel, and A. Aguzzi, Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration, Nat. Med., 10: 187–192, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• D.M. Klinman, M. Takeno, M. Ichino, M. Gu, G. Yamshchikov, G. Mor, and J. Conover, DNA vaccines: safety and efficacy issues, Springer Semin. Immunopathol., 19: 245–256, 1997. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• C.L. Cooper, H.L. Davis, M.L. Morris, S.M. Efler, A.M. Krieg, Y. Li, C. Laframboise, M.J. Al Adhami, Y. Khaliq, I. Seguin, and D.W. Cameron, Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine, Vaccine, 22: 3136–3143, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• X.P. Ioannou, P. Griebel, A. Mena, S.M. Gomis, D.L. Godson, G. Mutwiri, R. Hecker, L.A. Babiuk, and S. van Drunen Littel-van den Hurk, Safety of CpG oligodeoxynucleotides in veterinary species, Antisense Nucleic Acid Drug Dev., 13, 157–167, 2003. [CSA], [CROSSREF]
   PubMedGoogle Scholar
• J.P. Messina, G.S. Gilkeson, and D.S. Pisetsky, Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA, Journal of Immunology (Baltimore, Md.: 1950), 147: 1759–1764, 1991. [CSA]
   PubMed Web of Science ®Google Scholar
• G.S. Gilkeson, P. Ruiz, D. Howell, J.B. Lefkowith, and D.S. Pisetsky, Induction of immune-mediated glomerulonephritis in normal mice immunized with bacterial DNA, Clin. Immunol. Immunopathol., 68: 283–292, 1993. [CSA]
   PubMedGoogle Scholar
• G.S. Gilkeson, A.M. Pippen, and D.S. Pisetsky, Induction of cross-reactive anti-dsDNA antibodies in preautoimmune NZB/NZW mice by immunization with bacterial DNA, J. Clin. Invest., 95: 1398–1402, 1995. [CSA]
   PubMed Web of Science ®Google Scholar
• K. Hasegawa and T. Hayashi, Synthetic CpG oligodeoxynucleotides accelerate the development of lupus nephritis during preactive phase in NZB x NZWF1 mice, Lupus, 12: 838–845, 2003. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• E.A. Leadbetter, I.R. Rifkin, A.M. Hohlbaum, B.C. Beaudette, M.J. Shlomchik, and A. Marshak-Rothstein, Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors, Nature, 416: 603–607, 2002. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• G.A. Viglianti, C.M. Lau, T.M. Hanley, B.A. Miko, M.J. Shlomchik, and A. Marshak-Rothstein, Activation of autoreactive B cells by CpG dsDNA, Immunity, 19: 837–847, 2003. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• L. Rui, C.G. Vinuesa, J. Blasioli, and C.C. Goodnow, Resistance to CpG DNA-induced autoimmunity through tolerogenic B cell antigen receptor ERK signaling, Nat. Immunol., 4: 594–600, 2003. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• G.S. Gilkeson, J. Conover, M. Halpern, D.S. Pisetsky, A. Feagin, and D.M. Klinman, Effects of bacterial DNA on cytokine production by (NZB/NZW)F1 mice, J. Immunol., 161: 3890–3895, 1998. [CSA]
   PubMed Web of Science ®Google Scholar
• G. Mor, M. Singla, A.D. Steinberg, S.L. Hoffman, K. Okuda, and D.M. Klinman, Do DNA vaccines induce autoimmune disease? Hum Gene. Ther., 8: 293–300, 1997. [CSA]
   PubMed Web of Science ®Google Scholar
• O. Duramad, K.L. Fearon, B. Chang, J.H. Chan, J. Gregorio, R.L. Coffman, and F.J. Barrat, Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation, J. Immunol., 174: 5193–5200, 2005. [CSA]
   PubMed Web of Science ®Google Scholar
• X. Wu and S.L. Peng, Toll-like receptor 9 signaling protects against murine lupus, Arthritis Rheum., 54: 336–342, 2006. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• F. Obermeier, U.G. Strauch, N. Dunger, N. Grunwald, H.C. Rath, H. Herfarth, J. Scholmerich, and W. Falk, In vivo CpG DNA/toll-like receptor 9 interaction induces regulatory properties in CD4+CD62L+ T cells which prevent intestinal inflammation in the SCID transfer model of colitis, Gut, 54: 1428–1436, 2005. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• E.A. Moseman, X. Liang, A.J. Dawson, A. Panoskaltsis-Mortari, A.M. Krieg, Y.J. Liu, B.R. Blazar, and W. Chen, Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells, J. Immunol., 173: 4433–4442, 2004. [CSA]
   PubMed Web of Science ®Google Scholar
• V.V. Jain, K. Kitagaki, T. Businga, I. Hussain, C. George, P. O'Shaughnessy, and J.N. Kline, CpG-oligodeoxynucleotides inhibit airway remodeling in a murine model of chronic asthma, J. Allergy Clin. Immunol., 110: 867–872, 2002. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• G. Napolitani, A. Rinaldi, F. Bertoni, F. Sallusto, and A. Lanzavecchia, Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells, Nat. Immunol., 6: 769–776, 2005. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar